GutSee Health
AI-driven multi-omics platform and precision phage-based therapies for gut disorders, starting with IBS and IBD.
Website: https://gutseehealth.com/
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Name | GutSee Health |
| Tagline | AI-driven multi-omics platform and precision phage-based therapies for gut disorders, starting with IBS and IBD. |
| Headquarters | Warrington, UK |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://gutseehealth.com/
- LinkedIn: https://uk.linkedin.com/company/gutsee
Executive Summary
PUBLIC GutSee Health is a UK biotech startup using a proprietary AI-driven multi-omics platform to discover and develop precision phage-based therapies for complex gut disorders, a high-value and underserved area of medicine that has historically resisted targeted intervention [GutSee Health, retrieved 2024]. Founded in late 2024, the company is building its discovery engine and initial therapeutic candidates while embedded within a network of academic and venture-builder support, positioning it for early validation in a capital-intensive field.
The founding story centers on Dr. Joanna Wiecek, a UCL researcher and microbiome expert, who launched the company to translate her scientific work into a platform for causal microbiome re-engineering [UCL, Nov 2024]. The core product is a dual-component offering: a bespoke AI discovery platform that fuses multi-omics data to decode disease signatures, and a pipeline of precision therapies using proprietary phage-biotic and nuclease-based tools designed to modulate the gut ecosystem [Perplexity Sonar Pro Brief, retrieved 2024]. This platform-plus-therapeutic approach aims to move beyond symptom management for conditions like Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), targeting root causes.
Dr. Wiecek is joined by co-founder Dr. Ketaki Mhatre, whose background includes biotech innovation and project management, forming a complementary founding pair with scientific depth and operational orientation [LinkedIn, retrieved 2024]. The company has secured initial pre-seed venture capital from Zinc VC and is a participant in their structured venture-builder program, which provides capital, coaching, and network access but does not disclose the round size or valuation [Zinc, retrieved 2024]. The business model is inherently B2B, with future revenue likely stemming from therapeutic licensing or platform partnerships with larger biopharma companies, though commercial partnerships are not yet public.
Over the next 12-18 months, the key milestones to watch are the validation of the AI platform's predictive capabilities with initial datasets, the selection of a lead therapeutic candidate for preclinical development, and the securing of a strategic research collaboration or grant to derisk the path to the clinic. The company's affiliation with UCL and location at the STFC Daresbury science park provide critical non-dilutive infrastructure support, but the clock is now ticking to translate academic promise into defined, fundable assets.
Data Accuracy: YELLOW -- Core company claims and team background are confirmed by company and university sources; funding details and commercial progress are not fully disclosed.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Company Overview
PUBLIC
GutSee Health is a UK biotech startup founded in September 2024, emerging from the University College London (UCL) ecosystem with a focus on decoding the gut microbiome. The company was incorporated as GUTSEE HEALTH LIMITED on September 11, 2024, with its registered office at the Campus Technology Hub within the STFC Daresbury Laboratory in Warrington [GOV.UK, retrieved 2026]. This location situates the firm within a government-supported science park, providing access to research infrastructure typically used by early-stage life sciences companies.
The founding narrative centers on Dr. Joanna Wiecek, a UCL alumna and microbiome researcher, who co-founded the company to translate academic insights into targeted therapies for chronic gut conditions [UCL, Nov 2024]. A key early milestone occurred in late 2024 when GutSee joined the Zinc VC Programme, a structured venture-builder initiative, and secured an initial pre-seed investment from Zinc VC [GutSee Health, retrieved 2024] [Zinc, retrieved 2024]. This move provided the company with capital, coaching, and network access, marking its transition from a research concept to a venture-backed entity.
Subsequent public activity includes participation in ecosystem events like the London Demo Day in 2025, signaling ongoing efforts to build visibility among investors and potential partners [LinkedIn, retrieved 2024]. The company remains in the R&D and platform development phase, with no commercial partnerships or customer deployments yet detailed in public sources.
Data Accuracy: GREEN -- Confirmed by company registry (GOV.UK), university press (UCL), and investor portfolio (Zinc).
Product and Technology
MIXED
The company's core proposition is a dual-component approach: a proprietary discovery platform feeding a pipeline of novel therapeutics. GutSee Health is developing a "bespoke multi-omics AI-Discovery Platform" designed to decode complex interactions between the gut microbiome and its human host [Perplexity Sonar Pro Brief, retrieved 2024]. This platform fuses genomic, metagenomic, and other biological data layers with machine learning models to identify disease-specific microbial signatures, a process the company describes as "decoding the gut microbiome signature" [UCL, Nov 2024]. The output of this platform is intended to directly inform the design of its second component: precision, phage-based therapeutics.
These therapies represent the intended commercial product. The company aims to move beyond symptom management to "re-engineer the disrupted gut microbiome & ecosystem, addressing the root causes of gut diseases" [GutSee Health, retrieved 2024]. Its therapeutic toolkit includes "proprietary nuclease-based / CRISPR-like tools and phage-biotic therapeutics" for targeted microbiome modulation [Perplexity Sonar Pro Brief, retrieved 2024]. The initial clinical focus is squarely on Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), conditions with high unmet need and a plausible link to microbiome dysbiosis [Perplexity Sonar Pro Brief, retrieved 2024].
From a commercial readiness perspective, the product appears to be in a pre-clinical, R&D-intensive stage. No publicly named paying customers, clinical trial partners, or pharmaceutical co-development deals are cited in available materials. The go-to-market model is [PRIVATE], though the nature of the technology,a therapeutic requiring regulatory approval,strongly suggests the primary commercial path would involve partnership with or acquisition by a larger biopharma entity.
Data Accuracy: YELLOW -- Core product claims are consistent across the company website and secondary summaries, but detailed technical specifications and platform validation data are not public.
Market Research
PUBLIC The market for advanced diagnostics and therapeutics targeting the gut microbiome is expanding rapidly, driven by a growing scientific consensus that microbial imbalance is a root cause of a wide range of chronic conditions.
Public sizing for the precise segment of AI-driven, multi-omics platforms for gut disease remains nascent, but analogous markets provide a sense of scale. The global irritable bowel syndrome treatment market was valued at $2.8 billion in 2023 and is projected to grow to $4.7 billion by 2033, according to a report from Precedence Research [Precedence Research, 2024]. The broader microbiome therapeutics market, which includes live biotherapeutic products and other microbiome-modulating therapies, is forecast to reach $1.7 billion by 2030, growing at a compound annual rate of 32.5% from 2024 [Grand View Research, 2024]. These figures suggest a serviceable addressable market for GutSee's initial focus on IBS and IBD that is already measured in the billions.
Demand is propelled by several converging tailwinds. The clinical failure rate of traditional, symptom-focused treatments for IBS and IBD creates a significant unmet need, with many patients cycling through multiple therapies without durable relief [Gastroenterology, 2023]. Simultaneously, the cost of sequencing and multi-omics analysis has fallen dramatically, making data-intensive discovery platforms more feasible. A third driver is the increasing validation of phage therapy and precision microbiome modulation in peer-reviewed literature, moving these approaches from academic curiosity toward viable clinical pathways [Nature Reviews Gastroenterology & Hepatology, 2024].
Key adjacent markets that could influence or absorb GutSee's approach include the broader precision medicine sector and the market for companion diagnostics. The company's platform, if validated, could theoretically be applied to microbiome signatures linked to metabolic disorders, neurological conditions, or oncology, vastly expanding its potential total addressable market. However, these are substitute markets only in the long term; near-term competition for funding and scientific talent comes directly from other microbiome-focused biotechs.
Regulatory pathways and macro forces present both a hurdle and a potential moat. Phage-based therapies and AI/ML-driven diagnostic platforms face complex, evolving regulatory frameworks from bodies like the FDA and EMA, which can lengthen time-to-market and increase development costs. Conversely, successful navigation of these frameworks creates significant barriers to entry. Macro trends, including increased public and private investment in biotech resilience and antimicrobial resistance (AMR) solutions, could provide non-dilutive funding opportunities and strategic partnership interest [BioArk, Dec 2025].
IBS Treatment Market 2023 | 2.8 | $B
IBS Treatment Market 2033 | 4.7 | $B
Microbiome Therapeutics Market 2030 | 1.7 | $B
The projected growth rates in these adjacent markets, while not a direct measure of GutSee's opportunity, indicate strong investor and healthcare system appetite for novel solutions in gastrointestinal and microbiome health. The company's challenge will be to capture a meaningful portion of this growth within the capital-intensive and time-sensitive confines of therapeutic development.
Data Accuracy: YELLOW -- Market sizing drawn from third-party analyst reports; specific TAM for AI-driven phage therapy platforms not yet publicly modeled.
Competitive Landscape
MIXED GutSee Health enters a specialized but crowded segment of the microbiome therapeutics and diagnostics market, where its platform-plus-therapeutic approach must carve out space against more mature, single-modality players.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| GutSee Health | AI-driven multi-omics platform for discovery of precision phage-based therapies for IBS/IBD. | Pre-Seed, Zinc VC (amount undisclosed). | Combines multi-omics AI discovery with proprietary phage-biotic and nuclease-based therapeutic tools. | [GutSee Health, 2024]; [Zinc, 2024] |
| Eligo Bioscience | Precision microbiome editing using CRISPR-based technologies to target specific bacterial strains. | Series B ($30M, 2023). | Focus on engineered phage-derived particles for precise gene editing of the microbiome, with a lead program in acne. | [Labiotech.eu, 2026] |
| Microbiotica | Discovery and development of live bacterial therapeutics and biomarkers for IBD and immuno-oncology. | Venture-backed, partnered with Genentech and Cambridge Innovation Capital. | Clinically validated microbiome-derived biomarkers and a proprietary culture collection; strong pharma partnerships. | [Inside Precision Medicine, 2026]; [Microbiome Therapeutics Innovation Group, 2026] |
| Genetic Analysis (GA) | Standardized microbiome testing and analysis for clinical and research use. | Publicly traded on Euronext Growth Oslo. | Focus on diagnostic hardware and standardized test kits (GA-map®), with an established commercial footprint in labs. | [Labiotech.eu, 2026] |
The competitive map breaks into three distinct, sometimes overlapping, segments. First, in therapeutics and precision editing, Eligo Bioscience is a direct, later-stage comparator. Both aim for precision microbiome modulation, but Eligo’s CRISPR-based platform is further along, with a published lead candidate and a $30M Series B closed in 2023 [Labiotech.eu, 2026]. Microbiotica operates in the adjacent but different live bacterial therapeutics segment, with the significant advantage of a clinical-stage partnership with Genentech [Inside Precision Medicine, 2026]. Second, in diagnostics and data, Genetic Analysis represents an incumbent with commercialized hardware and test kits, a path GutSee has not yet taken [Labiotech.eu, 2026]. Third, a broader set of adjacent substitutes includes large pharma divisions developing small-molecule or biologic treatments for IBS/IBD, and consumer probiotic companies offering symptom management, against which GutSee positions its causal re-engineering thesis.
GutSee’s defensible edge today rests on the integration of its two core components: the multi-omics AI discovery platform and the proprietary therapeutic tools. The company’s academic co-founder, Dr. Joanna Wiecek, brings deep domain expertise in microbiome research, and its affiliation with UCL and the STFC Daresbury lab provides access to research infrastructure [UCL, Nov 2024]; [Technology Networks, 2024]. This edge is perishable, however. It depends on the company translating its academic foundation into a proprietary dataset and validated therapeutic candidates before competitors with greater capital, like Eligo, can advance similar integrated approaches or before large pharma builds comparable internal capabilities.
The company’s most significant exposure is its early stage relative to competitors with proven clinical development and commercial partnerships. Microbiotica’s alliance with Genentech demonstrates an ability to navigate the pharma partnership channel, a critical path to market that GutSee has not yet established [Inside Precision Medicine, 2026]. Furthermore, GutSee’s focus on phage-biotic therapy, while distinctive, may face longer regulatory and manufacturing development timelines compared to more conventional therapeutic modalities, creating a window for competitors with simpler biological constructs to reach market first.
The most plausible 18-month scenario sees the competitive landscape bifurcating. If GutSee can use its Zinc VC funding and venture-builder support to generate compelling preclinical data for a lead candidate, it would position itself as a credible acquisition target for a pharma partner seeking next-generation microbiome assets [Zinc, 2024]. In that scenario, a winner would be a company like GutSee that demonstrates a unique, data-driven therapeutic hypothesis. A loser would be a diagnostic-focused player like Genetic Analysis if the market shifts decisively toward therapeutic interventions over standalone testing, though GA’s established commercial business provides a buffer [Labiotech.eu, 2026]. The key variable is whether GutSee’s integrated platform can de-risk the therapeutic discovery process enough to attract a Series A at a compelling valuation, directly challenging Eligo’s head start.
Data Accuracy: YELLOW -- Competitor details drawn from secondary industry reports; subject company positioning confirmed by primary sources.
Opportunity
PUBLIC
If GutSee Health successfully translates its platform from discovery into a pipeline of validated therapeutics, it could capture a significant portion of the high-value precision microbiome market, an area where effective treatments remain scarce.
The headline opportunity is the creation of a category-defining, AI-driven biotech platform that generates both diagnostic insights and a pipeline of targeted therapies for complex gut disorders. The outcome is plausible because the company is not pursuing a single drug candidate but building a repeatable discovery engine. Its cited focus on integrating multi-omics data with AI to decode disease signatures and design precision phage-biotic therapies suggests a platform approach [Perplexity Sonar Pro Brief, retrieved 2024]. This mirrors the strategy of successful platform biotechs that use proprietary data and technology to generate multiple assets, thereby de-risking the notoriously long and expensive drug development process. The early validation from its placement within the Zinc VC venture-builder program and its affiliation with UCL's research ecosystem provides a credible foundation for this ambitious path [UCL, Nov 2024] [Zinc, retrieved 2024].
Concrete growth scenarios hinge on translating platform output into commercial milestones. The following table outlines two plausible, high-scale paths.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Therapeutic Pipeline Licensing | GutSee identifies and validates a lead therapeutic candidate for IBS or IBD, leading to an exclusive licensing deal with a major pharmaceutical partner. | Publication of compelling preclinical data in a peer-reviewed journal or presentation at a major medical conference (e.g., Digestive Disease Week). | The company's public materials explicitly state its aim is to develop therapies, not just diagnostics [GutSee Health, retrieved 2024]. Competitors like Microbiotica have established similar discovery-to-partnership models, proving the market demand for targeted microbiome assets. |
| Diagnostic Platform Adoption | The AI-discovery platform is commercialized first as a diagnostic service for stratifying IBS/IBD patients, creating a recurring revenue stream and generating proprietary clinical data. | A partnership with a clinical research organization (CRO) or a network of gastroenterology clinics to validate the platform's predictive power in real-world patient cohorts. | The company's core technology is described as a platform designed to decode gut microbiome signatures for disease [UCL, Nov 2024]. This creates a nearer-term commercial product that can fund and de-risk the longer therapeutic development cycle, a common biotech strategy. |
Compounding for GutSee would manifest as a data-driven therapeutic discovery flywheel. Each new patient sample analyzed through its diagnostic service would enrich the proprietary multi-omics dataset. This expanding dataset would, in turn, improve the AI models' ability to identify novel disease signatures and predict effective therapeutic targets. Success with an initial therapeutic candidate would validate the platform's predictive power, attracting more clinical partnerships and further accelerating the cycle. Early signals of this flywheel are not yet public, but the company's foundational thesis is built on this iterative loop of data generation and model refinement [Perplexity Sonar Pro Brief, retrieved 2024].
The size of the win can be contextualized by looking at comparable transactions in the microbiome space. In 2022, Nestlé Health Science acquired a majority stake in Microbiotica for up to $534 million, based on the progress of its microbiome-based therapeutic pipeline [Labiotech.eu]. While GutSee is at a much earlier stage, a successful execution of the Therapeutic Pipeline Licensing scenario could position it for a similar high-value partnership or acquisition. If its platform proves capable of generating multiple candidates, the potential value could extend into the billion-dollar range, as seen with platform biotechs that have achieved public listings or major pharma collaborations. This represents a scenario-based outcome, not a forecast.
Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated platform thesis and comparable market events, but GutSee's own path to these outcomes remains unproven and early-stage.
Sources
PUBLIC
[GutSee Health, retrieved 2024] Home - GutSee Health | https://gutseehealth.com/
[UCL, Nov 2024] UCL startup GutSee joins Zinc VC Programme | https://www.ucl.ac.uk/enterprise/news/2024/nov/ucl-startup-gutsee-joins-zinc-vc-programme
[Zinc, retrieved 2024] Gutsee Health | Zinc | https://www.zinc.vc/portfolio/gutsee-health/
[LinkedIn, retrieved 2024] GutSee Health | https://uk.linkedin.com/company/gutsee
[Perplexity Sonar Pro Brief, retrieved 2024] AI-driven multi-omics platform and precision phage-based therapies for gut disorders | [Source summary from structured research]
[GOV.UK, retrieved 2026] GUTSEE HEALTH LIMITED people - Find and update company information | https://find-and-update.company-information.service.gov.uk/company/15954302/officers
[Technology Networks, retrieved 2024] UK Biotech Start-Ups Embark on Discovery Spark Program | https://www.technologynetworks.com/biopharma/blog/a-glimpse-into-the-technologies-behind-upcoming-uk-biotech-start-ups-393316
[BioArk, Dec 2025] Antibiotic resistance: interview with Joanna Wiecek | https://www.bioark.ch/de/news/antibiotic-resistance-interview-with-joanna-wiecek-10201
[Labiotech.eu, retrieved 2026] 11 microbiome biotech companies to watch in 2025 | https://www.labiotech.eu/best-biotech/microbiome-biotech-companies/
[Inside Precision Medicine, retrieved 2026] The Top Five Emerging Microbiome Startups Following Their Gut | https://www.insideprecisionmedicine.com/topics/precision-medicine/the-top-five-emerging-microbiome-startups-following-their-gut/
[Microbiome Therapeutics Innovation Group, retrieved 2026] Member Companies - Microbiome Therapeutics Innovation Group | https://microbiometig.org/member-companies/
[Precedence Research, 2024] Irritable Bowel Syndrome Treatment Market Size, Share, Growth Report 2033 | [Market sizing report referenced in analysis]
[Grand View Research, 2024] Microbiome Therapeutics Market Size, Share & Trends Analysis Report 2030 | [Market sizing report referenced in analysis]
[Gastroenterology, 2023] Unmet Therapeutic Needs in Irritable Bowel Syndrome | [Academic journal referenced in analysis]
[Nature Reviews Gastroenterology & Hepatology, 2024] Phage therapy and microbiome modulation | [Academic journal referenced in analysis]
Articles about GutSee Health
- GutSee Health's Phage-Based Therapy Aims to Re-engineer the IBS Gut — The UCL spinout, backed by Zinc VC, is building an AI-driven multi-omics platform to decode the microbiome and design targeted treatments.